User profiles for D Spriggs
 | David SpriggsMassachusetts General Hospital Verified email at MGH.HARVARD.EDU Cited by 24067 |
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute …
The optimal design of phase II studies continues to be the subject of vigorous debate,
especially studies of newer molecularly targeted agents. The observations that many new …
especially studies of newer molecularly targeted agents. The observations that many new …
Genomic structure, induction, and production of TNF-alpha.
DR Spriggs, S Deutsch, DW Kufe - Immunology series, 1992 - europepmc.org
The TNF gene is located in close proximity to the HLA-B locus in both humans and mouse.
TNF has a high degree of sequence observation across species, and this is reflected in its …
TNF has a high degree of sequence observation across species, and this is reflected in its …
Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial
…, PS Teirstein, JF Tanguay, DJ Angiolillo, D Spriggs… - Jama, 2011 - jamanetwork.com
Context High platelet reactivity while receiving clopidogrel has been linked to cardiovascular
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …
Detection of circulating tumor necrosis factor after endotoxin administration
HR Michie, KR Manogue, DR Spriggs… - … England Journal of …, 1988 - Mass Medical Soc
Cytokines, products of stimulated macrophages, are thought to mediate many host responses
to bacterial infection, but increased circulating cytokine concentrations have not been …
to bacterial infection, but increased circulating cytokine concentrations have not been …
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention …
…, JD Jackman, IJ Sarembock, DJ Cohen, D Spriggs… - Jama, 2003 - jamanetwork.com
ContextThe direct thrombin inhibitor bivalirudin has been associated with better efficacy and
less bleeding than heparin during coronary balloon angioplasty but has not been widely …
less bleeding than heparin during coronary balloon angioplasty but has not been widely …
[HTML][HTML] Effect of platelet inhibition with cangrelor during PCI on ischemic events
…, F Tousek, J Tauth, D Spriggs… - … England Journal of …, 2013 - Mass Medical Soc
Background The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI)
is an important determinant of PCI-related ischemic complications. Cangrelor is a …
is an important determinant of PCI-related ischemic complications. Cangrelor is a …
Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial
…, L Cannon, JT Mann, JD Greenberg, D Spriggs… - Jama, 2005 - jamanetwork.com
ContextCompared with bare metal stents, drug-eluting stents reduce restenosis in noncomplex
lesions. The utility of drug-eluting stents has not been evaluated in more difficult stenoses.…
lesions. The utility of drug-eluting stents has not been evaluated in more difficult stenoses.…
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
…, W Tong, R Barakat, DR Spriggs - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS
that has progressed after doxorubicin treatment. We sought to determine the response to …
that has progressed after doxorubicin treatment. We sought to determine the response to …
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
…, S Pezzulli, C Canales, A Daud, DR Spriggs - Clinical cancer …, 2002 - AACR
Purpose: The purpose of this study was to evaluate the toxicity and pharmacodynamic
behavior of the novel proteasome inhibitor PS341 administered as a twice weekly iv bolus for 2 …
behavior of the novel proteasome inhibitor PS341 administered as a twice weekly iv bolus for 2 …
CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a gynecologic oncology …
…, FM Muggia, PG Rose, D Spriggs… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: There are limited data regarding unique clinical or laboratory features
associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), …
associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), …